ARCHIVES

Reinventing NCI: Natural Products Screen Closes; NCI Targets Drug Resistance

This article is from The Cancer Letter archive.

Vol. 22 No. 48 | December 13, 1996

Download PDF Visit The Full Archive

Related Articles

In Brief: House Cuts NCI Rescission To $7.73 Million; Weinhuse, Ultmann New ACCR, ASCO Presidents

May 8, 1981

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

Slamon, Sherr Win Landon-AACR Prizes

March 7, 2003

New CCP Lineup remains Unclear; 11 Bases OK’d

April 5, 1991

Named VP, Health sciences At UNM

February 11, 1994

NCCS Changes Web Domain; NCCN Plans Clinical Trials Network

June 7, 2002